Table 1.
Clinicopathological features of lung cancer patients in the study.
Fig 1.
The design and performance of MET exon 14 skipping mutation qPCR detection method.
(A) The schematic diagram of the primer and probe locations and amplicon sizes used in the qPCR assay. (B) The reprehensive amplification plot of the authentic plasmid standards, (C) The calibration curve for the MET exon 14 skipping mutation qPCR assay.
Fig 2.
Mutation sites, MET protein expression and histology of two MET exon 14 skipping mutation cases.
Schematic diagram of the mutation sites of the two MET exon 14 skipping mutation cases, qPCR amplification plot, and Sanger sequencing histograms (the first to third rows). The colors of qPCR curves in amplification plots were labeled as the marked colors for each target probe shown in Fig 1. Immunohistochemistry stains (the fourth row, 40X, scale bar = 20 μm); Hematoxylin and Eosin (H&E) stains (the fifth row, 20X, scale bar = 200 μm) for the cases. The case numbers were labeled according to the Table 2.
Table 2.
The clinicopathological features of patients with MET exon 14 skipping mutations, gene amplification and protein overexpression.
Fig 3.
The H&E, Immunohistochemistry and FISH results of two selected MET overexpression cases and 3 MET amplification cases.
H&E stains (the first row, 20X, scale bar = 200 μm); immunohistochemistry (the second row, 40X, scale bar = 20 μm); FISH (the third row, 63X). The case numbers were labeled according to the Table 2.